Table 1 Patient and disease characteristics based on STP type.

From: The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Characteristic, N = 385 (100%)

No.

True-EMD (n = 109, 28%)

PSK (n = 33, 9%)

No-STP (n = 243, 63%)

p value

Age in years, median, (range)

385

65.7 (31.2–88.7)

65.3 (39–84)

69.2 (37.1–92)

0.007

Female sex

385

49 (45%)

15 (45%)

118 (49%)

0.8

Race

385

    

 White

255

74 (68%)

19 (58%)

162 (67%)

0.5

 Black

87

20 (18%)

10 (30%)

57 (23%)

 

 Other

43

15 (14%)

4 (12%)

24 (10%)

 

Myeloma type

383

    

 IgA

77

24 (22%)

9 (28%)

44 (18%)

0.6

 IgG

209

57 (53%)

17 (53%)

135 (56%)

 

 Light chain only

91

24 (22%)

6 (16%)

61 (25%)

 

 Others

6

3 (3%)

0

3 (1.2%)

 

ECOG PS (n = 379)

376

    

 ≥2

96

24 (23%)

11 (33%)

61 (26%)

0.4

ISS

385

   

0.7

 Stage I

7

3 (2.7%)

0

4 (1.6%)

 

 Stage II

51

14 (13%)

2 (6%)

35 (14.4%)

 

 Stage III

37

12 (11%)

3 (9%)

22 (9%)

 

 Unknown/not reported

290

80 (73%)

28 (85%)

182 (75%)

 

R2-ISS

385

   

0.3

 Stage I

0

0

0

0

 

 Stage II

14

6 (5.5%)

1 (3%)

7 (3%)

 

 Stage III

58

20 (18%)

4 (12%)

34 (14%)

 

 Stage IV

20

3 (3%)

0

17 (7%)

 

 Unknown/not reported

293

80 (73%)

28 (85%)

185 (76%)

 

Cytogenetic risk

362

    

 Standard risk

243

65 (64%)

22 (69%)

156 (68%)

0.29

 Confirmed High-risk

65

24 (23.5%)

7 (22%)

34 (15%)

 

 Isolated 17p

54

13 (13%)

3 (9%)

38 (17%)

 

Plasma cell leukemia (any time)

385

5 (5.0%)

1 (3%)

6 (2.5%)

0.5

Triple-class refractory

385

95 (87%)

27 (82%)

200 (82%)

0.5

Penta-refractory

385

44 (40%)

11 (33%)

89 (37%)

0.7

Number of prior lines, median (range)

375

6.5 (3–16)

6 (2–18)

6 (2–17)

0.19

Prior BCMA-directed therapy

385

68 (62%)

17 (51.5%)

108 (44%)

0.008

  1. Not all percentages add up to 100% because of rounding. Triple-class refractory: defined as refractory to ≥1 immunomodulatory drug, ≥1 proteasome inhibitor, and ≥1 anti-CD38 monoclonal antibody. Penta-refractory: defined as refractory to ≥2 immunomodulatory drugs, ≥2 proteasome inhibitors, and ≥1 anti-CD38 monoclonal antibody. Cytogenetic risk: patients were classified into three cytogenetic risk groups based on a modified version of the 2025 IMS/IMWG consensus criteria: (1) standard risk, (2) confirmed high-risk, defined as t(4;14), t(14;16), or t(14;20) in combination with either gain/amp(1q) or del(1p), or concomitant gain/amp(1q) and del(1p) (including cases with concurrent del(17p)), and (3) isolated del(17p), categorized separately if not meeting criteria for confirmed high-risk, regardless of variant allele frequency or clonal fraction, given the absence of TP53 mutation data and incomplete FISH threshold information.
  2. STP soft tissue plasmacytoma, True-EMD soft tissue plasmacytomas non-contiguous with bone, PSK paraskeletal, bone-based soft tissue, BCMA B-cell maturation antigen, ECOG PS Eastern Cooperative Oncology Group Performance Status, R2-ISS 2nd revision of ISS.
Back to article page